Benchmark Biolabs of Lincoln, Neb., and AgriLabs of St. Joseph, Mo., announced April 17 the formation of VaxLiant, a joint venture designed to modernize how vaccines deliver antigens to prevent disease.
According to the announcement, VaxLiant offers a portfolio of ready-to-use and customizable adjuvants and technical and marketing expertise to help streamline the vaccine development process.
VaxLiant is headquartered at Benchmark Biolabs' facilities in Lincoln.
"What this means is that vaccine companies now have access to several readily available adjuvants that provide never-seen-before flexibility in delivering antigens at a competitive price," Steve Schram, VaxLiant co-founder and AgriLabs chief executive officer, said. "VaxLiant is also developing a line of customizable adjuvants that ultimately will enable companies of all sizes to provide vaccines that can meet specific needs of veterinarians and farmers. All of this is backed by an experienced support team with the know-how to make developing and manufacturing vaccines less challenging."
VaxLiant's antigen-delivery formulations can be used to improve immune response and deliver novel technologies as scientists look for new ways to manage highly contagious transboundary diseases, as well as to enhance vaccines used in conventional animal health programs, the announcement said.